IGMS News and Press, IGM Biosciences Inc. From 05/07/24

MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conferenc...

2024-04-22 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-17 08:48:28 ET More on IGM Biosciences IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points IGM Biosciences GAAP EPS of -$1.01 beats by $0.08, revenue of $0.7M misses by $0.07M RBC Capital upgrades IGM Biosciences to outperform ...

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and...

MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Stifel...

2024-03-13 09:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-08 15:30:01 ET Wedbush analyst issues NEUTRAL recommendation for IGMS on March 8, 2024 03:01PM ET. The previous analyst recommendation was Neutral. IGMS was trading at $12.68 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...

2024-03-07 17:21:26 ET More on IGM Biosciences IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points IGM Biosciences: A New Approach To Antibodies, But Not A Value Right Now RBC Capital upgrades IGM Biosciences to outperform Seeking Al...

MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided...

2024-02-12 15:09:25 ET Summary IGM Biosciences, Inc. is conducting phase 1b studies for imvotamab in patients with severe systemic lupus erythematosus and rheumatoid arthritis, with initial results expected in the second half of 2024. The global lupus market is projected to grow t...